Neuropathic Pain in Neurodegenerative Diseases: Pathophysiology and Treatment Advances

by

Neuropathic pain, a chronic and weakening condition, arises from direct rupture or disease affecting the somatosensory nervous system. This type of pain is not barely a symptom but a complex clinical entity that remarkably affects the quality of life in patients , mainly those with neurodegenerative diseases like amyotrophic lateral sclerosis(ALS) and Multiple sclerosis(MS) . The complex pathophysiology of neuropathic pain includes both peripheral and central nervous system mechanisms , paving way to altered neuronal excitability, inflammation and changes in synaptic function . In spite of notable developments in the underlying mechanisms, accurate cure remains uncertain. This article is involved in the pathophysiology of neuropathic pain involved with neurodegenerative diseases and highlights recent developments in its management.

Pathophysiology of Neuropathic Pain

The pathophysiology of neuropathic pain in neurodegenerative diseases is multidisciplinary including both peripheral and central nervous system changes . After nerve damage or degeneration , a series of events occurs at the molecular, cellular and systemic levels leading to pain. 

Peripheral Mechanisms

In the peripheral nervous system, nerve injury usually paves way to the release of inflammatory mediators such as cytokines , chemokines and growth factors which sensitize nociceptors, the sensory neurons that transmit pain signals. Additionally changes in ion channel expression, particularly sodium, calcium and potassium channels,contribute to the hyperexcitability of damaged nerves. This hyperexcitability manifests as spontaneous pain or amplifies responses to normally non painful stimuli (allodynia) and increased pain response to painful stimuli ( hyperalgesia).

One of the important features of neuropathic pain is the criteria of phenotypic switching in which injured sensory neurons alter their neurochemical profile. For instance, after nerve injury, neurons that mainly do not generate some neuropeptides or ion channels may begin to do so, paving way to altered pain signaling routes. Moreover, the sympathetic nervous system can become involved, where adrenergic receptors on non receptors enhance the sensitivity to noradrenaline, exacerbating pain.

Yearwise Publication Trend on “neurodegenerative diseases”

Find publication trends on relevant topics

Central Mechanisms

Central sensitization, a main component of neuropathic pain, including alterations in the spinal cord and brain that amplify pain signals. After peripheral nerve injury, enhanced activity in spinal dorsal horn neurons paving way to synaptic plasticity, featured by increased excitatory transmission and lowered inhibitory control. This results in a point where even low  level stimuli can generate pain. 

Glial cells, mainly microglia and astrocytes , play an important role in having central sensitization. With nerve injury , these glial cells become activated , releasing pro inflammatory cytokines , chemokines and growth factors that perpetuate neuronal hyperexcitability.Including,the loss of inhibitory interneurons and the downregulation of GABAergic (Gamma – aminobutyric acid – producing) pathways further exacerbate central sensitization.

Neurodegenerative diseases like ALS and MS, which includes progressive neuronal loss, contribute to the complexity of neuropathic pain. In ALS, for example , the degeneration of motor neurons paves way to both peripheral and central sensitization, while in MS, demyelination and subsequent axonal damage outcomes in abnormal pain processing.

Clinical Manifestations

Neuropathic pain in neurodegenerative diseases is often chronic and resistant to conventional analgesics. Patients may experience a range of symptoms, including burning sensations, electric shock like pain, and  aching pain. These symptoms can increase in intensity and may be accompanied by sensory deficits such as numbness or tingling.

In ALS , neuropathic pain is usually linked to the progressive loss of motor neurons, paving way to muscle wasting, spasticity and joint contractures which leads to pain. In MS, neuropathic pain can arise from lesions in both the central and peripheral nervous systems, with trigeminal neuralgia and Lhermitte’s signal ( a sudden electric shock sensation triggered by neck movement) being main pain syndromes related with the disease.

Advances in Treatment

The control of neuropathic pain in neurodegenerative diseases remains difficult due to the severity of the involved mechanisms and the chronic nature of the pain. However, recent innovations offer hope for more effective treatments.

Pharmacological Treatments

Several classes of drugs are commonly used to manage neuropathic pain, each targeting different aspects of the pain pathway.

Antidepressants: Tricyclic antidepressants (TCAs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are often the basic cure for neuropathic pain. They work by increasing the regulating  inhibitory pain pathways in the central nervous system. However, their use in patients with neurodegenerative diseases may be less by side effects, especially in older patients.

Anticonvulsants:Gabapentin and pregabalin are commonly used anticonvulsants that inhibit excitatory neurotransmitter release by blocking voltage gated calcium channels. 

Opioids: While opioids are efficient for many types of pain, their use in neuropathic pain is controversial due to the risk of tolerance, dependence, and side effects. They may be considered in cases where other treatments have failed, but long term use should be carefully analyzed.

Topical Agents: Lidocaine patches and capsaicin cream are topical cures that can be used to manage localized neuropathic pain. Lidocaine works by blocking sodium channels, thereby reducing neuronal excitability, a neuropeptide involved in pain transmission.

NMDA Receptor Antagonists: The N-methyl-D-aspartate (NMDA) receptor plays a crucial role in central sensitization. Ketamine, an NMDA receptor antagonist, has been shown to reduce pain in patients with neuropathic pain, although its use is often limited to refractory cases due to its psychotropic side effects.

Recent Publications on “neurodegenerative diseases”

Find publications on relevant topics

Non-Pharmacological Treatments

In addition to pharmacological interventions, non pharmacological treatments play an essential role in managing neuropathic pain in neurodegenerative diseases.

Physical Therapy: Physical therapy can help manage pain by improving muscle strength, flexibility, and mobility, thereby reducing the mechanical factors contributing to pain.

Neuromodulation: Techniques such as spinal cord stimulation (SCS) and transcutaneous electrical nerve stimulation (TENS) are used to modulate pain signals and provide relief in certain cases of neuropathic pain. These approaches are particularly useful when pain is localized and refractory to other treatments.

Future Directions

upcoming research into the mechanisms of neuropathic pain is routing the way for novel therapeutic methods. One promising area of research is the innovation  of biologic agents that target specific pain pathways, such as monoclonal antibodies against nerve growth factor (NGF). Gene therapy and stem cell therapy also hold capability for routing the underlying causes of neurodegenerative diseases and their related pain syndromes.

Additionally, improvements in neuroimaging techniques, such as functional MRI and PET scans, are increasing our understanding of the central mechanisms involved in neuropathic pain, leading to more targeted and personalized treatment approaches.

Conclusion

Neuropathic pain in neurodegenerative diseases is a difficult  and challenging condition that importantly  impacts patients quality of life. While important innovations have been made in understanding the underlying mechanisms and developing new treatments, much remains to be done. A multidisciplinary approach, combining pharmacological and non pharmacological treatments, offers the best way for effective pain management. As research continues to uncover the intricacies of neuropathic pain, new and more effective therapies will likely evolve, offering hope for enhanced results in patients with neurodegenerative diseases.

References

  1. H Vranken, J., 2012. Elucidation of pathophysiology and treatment of neuropathic pain. Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents), 12(4), pp.304-314.
  2. Bäumer, D., Talbot, K. and Turner, M.R., 2014. Advances in motor neurone disease. Journal of the Royal Society of Medicine, 107(1), pp.14-21.
  3. O’Driscoll, B.R., Howard, L.S., Earis, J. and Mak, V., 2017. British Thoracic Society Guideline for oxygen use in adults in healthcare and emergency settings. BMJ open respiratory research, 4(1), p.e000170.
  4. Brettschneider, J., Kurent, J. and Ludolph, A., 2013. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews, (6).
  5. Rafiq, M.K., Proctor, A.R., McDermott, C.J. and Shaw, P.J., 2012. Respiratory management of motor neurone disease: a review of current practice and new developments. Practical neurology, 12(3), pp.166-176.
  6. Tomik, B. and Guiloff, R.J., 2010. Dysarthria in amyotrophic lateral sclerosis: A review. Amyotrophic Lateral Sclerosis, 11(1-2), pp.4-15.
  7. Belić, M., Bobić, V., Badža, M., Šolaja, N., Đurić-Jovičić, M. and Kostić, V.S., 2019. Artificial intelligence for assisting diagnostics and assessment of Parkinson’s disease—A review. Clinical neurology and neurosurgery, 184, p.105442.

Top Experts on “neurodegenerative diseases“